Search hospitals

>

Missouri

>

Springfield

Mercy Hospital Springfield

Claim this profile

Springfield, Missouri 65804

Global Leader in Breast Cancer

Global Leader in Lung Cancer

Conducts research for Ovarian Cancer

Conducts research for Breast cancer

Conducts research for Cancer

397 reported clinical trials

3 medical researchers

Photo of Mercy Hospital Springfield in SpringfieldPhoto of Mercy Hospital Springfield in SpringfieldPhoto of Mercy Hospital Springfield in Springfield

Summary

Mercy Hospital Springfield is a medical facility located in Springfield, Missouri. This center is recognized for care of Breast Cancer, Lung Cancer, Ovarian Cancer, Breast cancer, Cancer and other specialties. Mercy Hospital Springfield is involved with conducting 397 clinical trials across 514 conditions. There are 3 research doctors associated with this hospital, such as Jay W Carlson, Madhu Kalyan Pendurthi, MD, and Sunthosh V. Parvathaneni, MD FHRS FACC.

Area of expertise

1

Breast Cancer

Global Leader

Mercy Hospital Springfield has run 65 trials for Breast Cancer. Some of their research focus areas include:

Stage IV
HER2 negative
ER positive
2

Lung Cancer

Global Leader

Mercy Hospital Springfield has run 56 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage II
Stage I

Top PIs

Clinical Trials running at Mercy Hospital Springfield

Lung Cancer

Bladder Cancer

Breast Cancer

Prostate Cancer

Kidney Cancer

Breast cancer

Colorectal Cancer

Esophageal cancer

Pancreatic Cancer

Ovarian Cancer

Image of trial facility.

Proton Craniospinal Radiation

for Cancer in the Brain and Spinal Cord

This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal fluid filled space that surrounds the brain and spinal cord (leptomeningeal metastasis). Patients with leptomeningeal metastasis (LM) may develop multiple areas of nervous system (neurologic) impairment that can be life-threatening. Radiation therapy (RT) effectively relieves local symptoms due to LM. RT uses high energy radiography (x-rays), particles, or radioactive seeds to kill cancer cells and shrink tumors. IFRT is commonly used to treat symptoms of LM. IFRT is radiation treatment that uses x-rays to treat specific areas of LM and to relieve and/or prevent symptoms. pCSI uses protons that can be directed with more accuracy than x-rays which allows treatment of the entire central nervous system space containing the cerebrospinal fluid (CSF), brain, and spinal cord. The pCSI treatment could delay the worsening of LM. Giving pCSI may be better than IFRT in treating LM in patients with breast or non-small cell lung cancer.

Recruiting

2 awards

Phase 3

3 criteria

Image of trial facility.

High-Dose Radiation + Chemotherapy and Immunotherapy

for Non-Small Cell Lung Cancer

This trial tests whether adding a precise form of radiation therapy to the usual treatment improves outcomes for patients with advanced lung cancer that can't be operated on. The goal is to see if this combination helps patients live longer and prevents cancer from worsening. This form of radiation therapy has shown promise in improving survival rates in patients with various stages of lung cancer.

Recruiting

2 awards

Phase 3

14 criteria

Image of trial facility.

Treatment Timing

for Non-Small Cell Lung Cancer

This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.

Recruiting

2 awards

Phase 3

4 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Mercy Hospital Springfield?

Where is Mercy Hospital Springfield located?

Who should I call to ask about financial aid or insurance network?

What insurance does Mercy Hospital Springfield accept?

What awards or recognition has Mercy Hospital Springfield received?